Optimizing the Use of Sunitinib in Metastatic Renal Cell Carcinoma: An Update From Clinical Practice

REFERENCES

• Motzer, R.J.; Michaelson, M.D.; Redman, B.G.; Hudes, G.R.; Wilding, G.; Figlin, R.A.; Ginsberg, M.S.; Kim, S.T.; Baum, C.M.; DePrimo, S.E.; Li, J.Z.; Bello, C.L.; Theuer, C.P.; George, D.J.; Rini, B.I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24, 16–24.
   PubMed Web of Science ®Google Scholar
• Motzer, R.J.; Rini, B.I.; Bukowski, R.M.; Curti, B.D.; George, D.J.; Hudes, G.R.; Redman, B.G.; Margolin, K.A.; Merchan, J.R.; Wilding, G.; Ginsberg, M.S.; Bacik, J.; Kim, S.T.; Baum, C.M.; Michaelson, M.D. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006, 295, 2516–2524.
   PubMed Web of Science ®Google Scholar
• Motzer, R.J.; Hutson, T.E.; Tomczak, P.; Michaelson, M.D.; Bukowski, R.M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S.T.; Chen, I.; Bycott, P.W.; Baum, C.M.; Figlin, R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356, 115–124.
   PubMed Web of Science ®Google Scholar
• Motzer, R.J.; Hutson, T.E.; Tomczak, P.; Dror Michaelson, M.; Bukowski, R.M.; Oudard, S.; Negrier, S.; Szczylik, C.; Pili, R.; Bjarnason, G.A.; Garcia-del-Muro, X.; Sosman, J.A.; Solska, E.; Wilding, G.; Thompson, J.A.; Kim, S.T.; Chen, I.; Huang, X.; Figlin, R.A. Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27, 3584–3590.
   PubMed Web of Science ®Google Scholar
• Ljungberg, B.; Hanbury, D.C.; Kuczyk, M.A.; Merseburger, A.S.; Mulders, P.F.A.; Patard, J-J.; Sinescu, I.C. Guidelines on Renal Cell Carcinoma. European Association of Urology. http://www.uroweb.org/fileadmin/tx_eauguidelines/2009/Full/RCC.pdf
   Google Scholar
• Pfizer Inc. SUTENT, Summary of Product Characteristics. October 2009. http://www.ema.europa.eu/humandocs/PDFs/EPAR/sutent/emea-combined-h687en.pdf
   Google Scholar
• Houk, B.E.; Bello, C.L.; Poland, B.; Rosen, L.S.; Demetri, G.D.; Motzer, R.J. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chem Book Pharmacol. 2009 Dec 5. [Epub ahead of print]
   Google Scholar
• Motzer, R.J.; Figlin, R.; Hutson, T.E.; Tomczak, P.; Bukowski, R.; Rixe, O.; Bjarnason, G.A.; Kim, S.T.; Chen, I.; Michaelson, D. Sunitinib versus interferon-alfa (IFN−) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J Clin Oncol 2007, 25(Suppl. 18S), 5024.
   Google Scholar
• Gore, M.E.; Szczylik, C.; Porta, C.; Bracarda, S.; Bjarnason, G.A.; Oudard, S.; Hariharan, S.; Lee, S.H.; Haanen, J.; Castellano, D.; Vrdoljak, E.; Schoffski, P.; Mainwaring, P.; Nieto, A.; Yuan, J.; Bukowski, R. Safety and efficacy of sunitinib with subpopulation analysis in an expanded-access trial of metastatic renal cell carcinoma. Lancet Oncol 2009, 10, 757–763.
   PubMed Web of Science ®Google Scholar
• Garsa, A.A.; McLeod, H.L.; Marsh, S. CYP3A4 and CYP3A5 genotyping by pyrosequencing. BMC Med Genet 2005, 6, 19.
   PubMed Web of Science ®Google Scholar
• Ingleman-Sundberg, M.; Sim, S.C.; Gomez, A.; Rodriguez-Antona, C. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007, 116, 496–526.
   PubMed Web of Science ®Google Scholar
• Lynch, T.; Price, A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician 2007, 76, 391–396.
   PubMed Web of Science ®Google Scholar
• Negrier, S.; Ravaud, A. Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management. Eur J Cancer Suppl 2007, 5, 12–19.
   Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. V.1.2008. http://www.nccn.org/professionals/physician_gls/PDF/fatigue.pdf
   Google Scholar
• Rini, B. I.; Tamaskar, I.; Shaheen, P.; Salas, R.; Garcia, J.; Wood, L.; Reddy, S.; Dreicer, R.; Bukowski, R.M. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst 2007, 99, 81–83.
   PubMed Web of Science ®Google Scholar
• Schöffski, P.; Wolter, P.; Himpe, D.R.; Dycher, S.S.; Baum, C.M.; Prenen, H.; Wilders, H.; Bex, A.; Dumez, H. Sunitinib-related thyroid dysfunction: a single-center retrospective and prospective evaluation. J Clin Oncol 2006, 24, 3092.
   Google Scholar
• Wolter, P.; Stephan, C.; Decallonne, B.; Dumez, H.; Fieuws, S.; Wildiers, H.; Clement, P.; Debaere, D.; Van Oosteron, A.; Schöffski, P. Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC). Poster presented at the 44th Annual Meeting of the American Society of Clinical Oncology, Chicago, Illinois, 30 May–3 June 2008. (abstract 5126).
   Google Scholar
• Benson, A.B., III; Ajani, J.A.; Catalano, R.B.; Engelking, C.; Kornblau, S.M.; Martenson, J.A., Jr.; McCallum, R.; Mitchell, E.P.; O’Dorisio, T.M.; Vokes, E.E.; Wadler, S. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 2004, 22, 2918–2926.
   PubMed Web of Science ®Google Scholar
• Porta, C.; Szczylik, C.; Bracarda, S.; Hawkins, R. Short and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma. J Clin Oncol 2008, 26: (Abstract 5114; poster presentation)
   PubMedGoogle Scholar
• ESMO Guidelines Working Group. ChemBookapy-induced nausea and vomiting: ESMO Clinical Recommendations for prophylaxis. Ann Surg Oncol. 2007, 18, (Suppl 2), ii83–ii85.
   Google Scholar
• The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC). Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugis International Antiemetic Consensus Conference. Ann Surg Oncol. 2004, 17, 20–8.
   Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Antiemesis. NCCN. 2008, http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf
   Google Scholar
• Navari, R.M.; Koeller, J.M. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother 2003, 37, 1276–1286.
   PubMed Web of Science ®Google Scholar
• Robert, C.; Faivre, S.; Raymond, E.; Armand, J.P.; Escudier, B. Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors? Ann Intern Med 2005, 143, 313–314.
   PubMed Web of Science ®Google Scholar
• Webster-Gandy, J.D.; How, C.; Harrold, K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs 2007, 11, 238–246.
   PubMed Web of Science ®Google Scholar
• Veronese, M.L.; Mosenkis, A.; Flaherty, K.T.; Gallagher, M.; Stevenson, J.P. Mechanisms of hypertension associated with BAY 43–9006. J Clin Oncol 2006, 24, 1363–1369.
   PubMed Web of Science ®Google Scholar
• Sane, D.C.; Anton, L.; Brosnihan, K.B. Angiogenic growth factors and hypertension. Angiogenesis 2004, 7, 193–201.
   PubMedGoogle Scholar
• Struijker Boudier, H.A.; le Noble, J.L.; Messing, M.W.; Huijberts, M.S.; le Noble, F.A.; van, E.H. The microcirculation and hypertension. J Hypertens Suppl 1992, 10, S147–S156.
   PubMedGoogle Scholar
• Chu, T.F.; Rupnick, M.A.; Kerkela, R.; Dallabrida, S.M.; Zurakowski, D.; Nguyen, L.; Woulfe, K.; Pravda, E.; Cassiola, F.; Desai, J.; George, S.; Morgan, J.A.; Harris, D.M.; Ismail, N.S.; Chen, J.H.; Schoen, F.J.; Van den Abbeele, A.D.; Demetri, G.D.; Force, T.; Chen, M.H. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370, 2011–2019.
   PubMed Web of Science ®Google Scholar
• Schmidinger, M.; Zielinski, C.C.; Vogl, U.M.; Bojic, A.; Bojic, M.; Schukro, C.; Ruhsam, M.; Hejna, M.; Schmidinger, H. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26, 5204–5212.
   PubMed Web of Science ®Google Scholar
• Gillessen, S.; Graf, L.; Korte, W.; Cerny, T. Macrocytosis and cobalamin deficiency in patients treated with sunitinib. N Eng J Med 2007, 356, 2330–2331.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Prevention and Treatment of Cancer-related Infections. 2009 http://www.nccn.org/professionals/physician_gls/PDF/infections.pdf
   Google Scholar
• Martin, G.; Bellido, L.; Cruz, J.J. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol 2007, 25, 3559.
   PubMed Web of Science ®Google Scholar
• Locatelli, F.; Rossi, F.. Incidence and pathogenesis of tumor lysis syndrome. Contrib Nephrol 2005;147, 61–68.
   PubMed Web of Science ®Google Scholar
• Zojer, N.; Ludwig, H. Hematological emergencies. Ann Oncol 2007;18 Suppl 1:i45–i48
   PubMedGoogle Scholar
• Nicholaou, T.; Wong, R.; Davis, I.D. Tumour lysis syndrome in a patient with renal-cell carcinoma treated with sunitinib malate. Lancet 2007, 369, 1923–1924.
   PubMed Web of Science ®Google Scholar
• Escudier, B.; Pluzanska, A.; Koralewski, P.; Ravaud, A.; Bracarda, S.; Szczylik, C.; Chevreau, C.; Filipek, M.; Melichar, B.; Bajetta, E.; Gorbunova, V.; Bay, J.O.; Bodrogi, I.; Jagiello-Gruszfeld, A.; Moore, N. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007, 370, 2103–2111.
   PubMed Web of Science ®Google Scholar
• Escudier, B.; Eisen, T.; Stadler, W.M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A.A.; Rolland, F.; Demkow, T.; Hutson, T.E.; Gore, M.; Freeman, S.; Schwartz, B.; Shan, M.; Simantov, R.; Bukowski, R. M. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356, 125–134.
   PubMed Web of Science ®Google Scholar
• Hudes, G.; Carducci, M.; Tomczak, P.; Dutcher, J.; Figlin, R.; Kapoor, A.; Staroslawska, E.; Sosman, J.; McDermott, D.; Bodrogi, I.; Kovacevic, Z.; Lesovoy, V.; Schmidt-Wolf, I. G.; Barbarash, O.; Gokmen, E.; O’Toole, T.; Lustgarten, S.; Moore, L.; Motzer, R.J. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007, 356, 2271–2281.
   PubMed Web of Science ®Google Scholar
• Kay, A.; Motzer, R.J.; Figlin, R.A.; Escudier, B.; Oudard, S.; Porta, C.; Hutson, T.E.; Bracarda, S.; Hollaender, N.; Urbanowitz, G.; Ravaud, A. Updated data from a phase 3 trial of everolimus (RAD001) versus placebo in patients with metastatic renal cell carcinoma. Eur Urol Suppl 2009, 8, 185 (poster presentation).
   Google Scholar
• Sternberg, C.N.; Davis, I.D.; Mardiak, J.; Szczylik, C.; Lee, E.; Wagstaff, J.; Barrios, C.H.; Salman, P.; Gladkov, O.A.; Kavina, A.; Zarbá, J.J.; Chen, M.; McCann, L.; Pandite, L.; Roychowdhury, D.F.; Hawkins, R.E. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol. 2010 Feb 20; 28(6):1061–8. Epub 2010 Jan 25.
   PubMed Web of Science ®Google Scholar